Published in Gastroenterology Week, June 9th, 2008
"The median age of the patients was 60 years, and 86.2% were men. 18.5% and 81.5% of the patients were diagnosed as TNM stage M and IV-A, respectively. Treatment response was assessed 4 mo after initiation of RT. Tumor regression rate I mo after initiation of RT (TRR1m) was also assessed. Duration of survival was calculated from the initiation of RT. The objective treatment response was 56.9%. The...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gastroenterology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.